FR2974088A1 - Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux - Google Patents

Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux Download PDF

Info

Publication number
FR2974088A1
FR2974088A1 FR1153200A FR1153200A FR2974088A1 FR 2974088 A1 FR2974088 A1 FR 2974088A1 FR 1153200 A FR1153200 A FR 1153200A FR 1153200 A FR1153200 A FR 1153200A FR 2974088 A1 FR2974088 A1 FR 2974088A1
Authority
FR
France
Prior art keywords
alkyl
group
heterocycle
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
FR1153200A
Other languages
English (en)
French (fr)
Inventor
Remi Rabot
Karim Bedjeguelal
El Bachir Kaloun
Philippe Schmitt
Nicolas Rahier
Patrice Mayer
Emmanuel Fournier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR1153200A priority Critical patent/FR2974088A1/fr
Priority to ARP120101242A priority patent/AR085987A1/es
Priority to TW101112790A priority patent/TWI560187B/zh
Priority to BR112013026355A priority patent/BR112013026355A2/pt
Priority to US14/111,098 priority patent/US9085575B2/en
Priority to HK14103508.3A priority patent/HK1190397B/xx
Priority to CA2832704A priority patent/CA2832704A1/en
Priority to MX2013011854A priority patent/MX2013011854A/es
Priority to KR1020137029401A priority patent/KR20140023341A/ko
Priority to PCT/EP2012/056637 priority patent/WO2012140114A1/en
Priority to CN201280023479.XA priority patent/CN103534254B/zh
Priority to RU2013148922/04A priority patent/RU2013148922A/ru
Priority to AU2012241891A priority patent/AU2012241891B2/en
Priority to EP12714688.4A priority patent/EP2697222A1/en
Priority to JP2014504312A priority patent/JP5972964B2/ja
Publication of FR2974088A1 publication Critical patent/FR2974088A1/fr
Priority to ZA2013/07783A priority patent/ZA201307783B/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1153200A 2011-04-12 2011-04-12 Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux Pending FR2974088A1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR1153200A FR2974088A1 (fr) 2011-04-12 2011-04-12 Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
ARP120101242A AR085987A1 (es) 2011-04-12 2012-04-11 Compuestos tri- y tetraciclicos pirazol[3,4-b]piridina como agentes antineoplasicos
TW101112790A TWI560187B (en) 2011-04-12 2012-04-11 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
MX2013011854A MX2013011854A (es) 2011-04-12 2012-04-12 Compuestos de pirazol[3,4-b]piridina tri- y tetraciclica como agentes antineoplasicos.
CN201280023479.XA CN103534254B (zh) 2011-04-12 2012-04-12 作为抗肿瘤剂的三环和四环吡唑并[3,4-b]吡啶化合物
HK14103508.3A HK1190397B (en) 2011-04-12 2012-04-12 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
CA2832704A CA2832704A1 (en) 2011-04-12 2012-04-12 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
BR112013026355A BR112013026355A2 (pt) 2011-04-12 2012-04-12 compostos de pirazolo[3,4-b]piridina tri- e tetracíclicos como agente antineoplásico
KR1020137029401A KR20140023341A (ko) 2011-04-12 2012-04-12 항신생물제로서의3- 및 4환성 피라졸로[3,4-b]피리딘 화합물
PCT/EP2012/056637 WO2012140114A1 (en) 2011-04-12 2012-04-12 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
US14/111,098 US9085575B2 (en) 2011-04-12 2012-04-12 Tri- and tetracyclic pyrazolo[3,4-B]pyridine compounds as antineoplastic agent
RU2013148922/04A RU2013148922A (ru) 2011-04-12 2012-04-12 Три- и тетрациклические пиразоло[3,4-в]пиридины в качестве антинеопластического средства
AU2012241891A AU2012241891B2 (en) 2011-04-12 2012-04-12 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
EP12714688.4A EP2697222A1 (en) 2011-04-12 2012-04-12 Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
JP2014504312A JP5972964B2 (ja) 2011-04-12 2012-04-12 抗腫瘍剤としての三環式および四環式ピラゾロ［３，４−ｂ］ピリジン化合物
ZA2013/07783A ZA201307783B (en) 2011-04-12 2013-10-18 Tri-and tetracylic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1153200A FR2974088A1 (fr) 2011-04-12 2011-04-12 Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux

Publications (1)

Publication Number Publication Date
FR2974088A1 true FR2974088A1 (fr) 2012-10-19

Family

ID=44512344

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1153200A Pending FR2974088A1 (fr) 2011-04-12 2011-04-12 Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux

Country Status (15)

Country Link
US (1) US9085575B2 (enExample)
EP (1) EP2697222A1 (enExample)
JP (1) JP5972964B2 (enExample)
KR (1) KR20140023341A (enExample)
CN (1) CN103534254B (enExample)
AR (1) AR085987A1 (enExample)
AU (1) AU2012241891B2 (enExample)
BR (1) BR112013026355A2 (enExample)
CA (1) CA2832704A1 (enExample)
FR (1) FR2974088A1 (enExample)
MX (1) MX2013011854A (enExample)
RU (1) RU2013148922A (enExample)
TW (1) TWI560187B (enExample)
WO (1) WO2012140114A1 (enExample)
ZA (1) ZA201307783B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
JP6487527B2 (ja) 2014-07-04 2019-03-20 チル ファーマシューティカル カンパニー リミテッド スピロ環アリールリン酸化物及びアリールリン硫化物（ｓｐｉｒｏｃｙｃｌｉｃ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｏｘｉｄｅ ａｎｄ ａｒｙｌ ｐｈｏｓｐｈｏｒｕｓ ｓｕｌｆｉｄｅ）
CN104447736B (zh) * 2014-10-14 2016-06-08 雅安职业技术学院 一种veranamine的合成方法
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9974784B2 (en) * 2015-01-21 2018-05-22 The Texas A&M University System Inhibitors of activin-like receptor kinases
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US20230303570A1 (en) * 2020-08-07 2023-09-28 Abm Therapeutics Corporation Kinase inhibitors and uses thereof
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之三環雜環
CN118891264A (zh) 2022-08-01 2024-11-01 齐鲁制药有限公司 螺环胺类芳基磷氧化合物的晶型及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032515A1 (en) * 2003-07-23 2007-02-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008002165A (es) * 2005-08-16 2008-04-29 Irm Llc Compuestos y composiciones como inhibidores de la proteina cinasa.
CN101525497B (zh) * 2008-03-06 2012-07-04 中国科学院理化技术研究所 吡唑啉吡啶并苯并香豆素荧光染料衍生物及其合成方法和用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032515A1 (en) * 2003-07-23 2007-02-08 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
US20100113415A1 (en) * 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GUO C ET AL: "Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazo lo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 20, no. 9, 1 May 2010 (2010-05-01), pages 2785 - 2789, XP027012833, ISSN: 0960-894X, [retrieved on 20100317] *
SHARIFA SOLTAN AL-KAABI ET AL: "STUDIES ON FUSED 2(1H)-PYRIDENETHIONES: NEW ROUTES FOR THE SYNTHESIS OF FUSED 1H-PYRAZOLO not 3,4-B 3/4 PYRIDINES AND FUSED THIENO not 2,3-B 3/4 PYRIDINES", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, CHEMICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 65, no. 8, 1 August 1992 (1992-08-01), pages 2241 - 2245, XP001068712, ISSN: 0009-2673 *

Also Published As

Publication number Publication date
US9085575B2 (en) 2015-07-21
AU2012241891A1 (en) 2013-10-31
WO2012140114A1 (en) 2012-10-18
MX2013011854A (es) 2013-11-01
JP2014510774A (ja) 2014-05-01
KR20140023341A (ko) 2014-02-26
EP2697222A1 (en) 2014-02-19
TW201247665A (en) 2012-12-01
CN103534254A (zh) 2014-01-22
TWI560187B (en) 2016-12-01
CN103534254B (zh) 2015-11-25
RU2013148922A (ru) 2015-05-20
AR085987A1 (es) 2013-11-13
CA2832704A1 (en) 2012-10-18
AU2012241891B2 (en) 2016-06-16
ZA201307783B (en) 2015-01-28
HK1190397A1 (zh) 2014-07-04
BR112013026355A2 (pt) 2016-12-27
US20140031362A1 (en) 2014-01-30
JP5972964B2 (ja) 2016-08-17

Similar Documents

Publication Publication Date Title
AU2012241891B2 (en) Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
EP2488519B1 (en) Pyrazolopyridine derivatives as anticancer agent
TWI329644B (en) Novel pyrrole derivatives as pharmaceutical agents
US20040044021A1 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
WO2007032466A1 (ja) 複素環化合物、その製造方法並びに用途
EP3426244A1 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
WO2002102807A1 (en) Novel isoxazolopyridone derivatives and use thereof
WO2010058314A1 (en) Hydroxyquinolin-2(1h)-ones and derivatives thereof
AU2006259474B2 (en) Androgen receptor modulator compounds and methods
JP2003516989A (ja) Ｇａｂａ受容体リガンドとしてのピラゾロ−ピリジン誘導体
CA3128846A1 (en) Difluoromethylene compound
AU2017373758A1 (en) Compounds and pharmaceutical compositions for modulating SGK activity, and methods thereof
CN106459060A (zh) 作为磷酸二酯酶10a抑制剂的稠合的三唑衍生物
CN109134463B (zh) β-咔啉类5型磷酸二酯酶抑制剂及其制备方法和用途
JP2010501641A (ja) Ｈｓｐ９０阻害剤として有用な１ｈ−ピロロ［２，３−ｂ］ピリジン誘導体
AU2003277562B2 (en) Pyrazolonaphthyridine derivative
JP2021011492A (ja) ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物
CN116375728B (zh) 噻吩吡咯并三嗪酮类化合物及其用途
TW202421119A (zh) 作為組蛋白去乙醯酶６抑制劑之１，３，４－㗁二唑衍生化合物及其用途
FR2972454A1 (fr) Nouveaux derives dihydro-oxazolobenzodiazepinones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2933983A1 (fr) Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
TW202227447A (zh) 嘧啶酮類化合物及其用途
HK1190397B (en) Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7